Type 1 diabetes: early diagnosis and treatment prospects

I. L. Alimova

doi:10.21508/1027-4065-2025-70-6-5-10

Type 1 diabetes: early diagnosis and treatment prospects

I. L. Alimova

https://doi.org/10.21508/1027-4065-2025-70-6-5-10

Full Text:

PDF (Rus)

Generate QR code

Abstract

The article presents epidemiological indicators of type 1 diabetes mellitus in children, data on genetic and environmental risk factors for the development of type 1 diabetes mellitus, classification of type 1 diabetes mellitus stages that reflects the continuum of disease development from the appearance of autoantibodies to clinical symptoms. The article focuses on the preclinical stages of type 1 diabetes mellitus and the importance of early diagnosis for potential prevention and slowing down the progression of the disease. The article emphasizes the need for a comprehensive interdisciplinary approach to screening, early diagnosis of type 1 diabetes mellitus, and patient management programs, including in primary healthcare settings.

Keywords

children, type 1 diabetes mellitus, preclinical stages, autoantibodies, screening

About the Author

I. L. Alimova

Smolensk State Medical University
Russian Federation

214019, Smolensk

References

1. Laptev D.N., Bezlepkina O.V., Sheshko E.L., Aleksandrova G.A., Chumakova O.V., Krestovskaya N.M. et al. Main epidemiological indicators of type 1 diabetus mellitus in children in the Russian Federation for 2014–2023. Problemy ehndokrinologii. 2024; 70(5): 76–83. (in Russ) DOI: 10.14341/probl13515

2. Rawshan А., Sattar N., Franzén S., Rawshani А., Hattersley A.T., Svensson А-М., et al. Excess mortality and cardiovascular disease in type 1 diabetes in relation to age at onset: a nationwide study of 27,195 young adults with diabetes. Lancet. 2018; 392(10146): 477–486. DOI: 10.1016/S0140-6736(18)31506-X

3. Luckett A.M., Weedon M.N., Hawkes G., Leslie R. D., Oram R.A., Grant S.F.A. Utility of genetic risk scores in type 1 diabetes. Diabetologia. 2023; 66: 1589–1600. DOI: 10.1007/s00125-023-05955-y

4. Sims E.K., Besser R.E.J., Dayan C., Rasmussen C.G., Greenbaum C., Griffin K.J., et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes. 2022; 71(4): 610–623. DOI: 10.2337/dbi20-0054

5. Akil A.A.S., Yassin E., Al-Maraghi A., Aliyev E., Al-Malki K., Fakhro K.A. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. Journal of Translational Medicine. 2021; 19(1): 137. DOI: 10.1186/s12967-021-02778-6

6. Clinical guidelines of Ministry of Health of Russia«Diabetes mellitus type 1 in childhood», 2025 (in Russ). https://cr.minzdrav.gov.ru/preview-cr/287_3 Ссылка активна на 15.10.2025

7. Phillip М., Achenbach Р., Addala А., Albanese-O’Neill А., Battelinо Т., Bell K.J., et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024; 67: 1731–1759. DOI: 10.1007/s00125-024-06205-5

8. Jacobsen L.M., Bocchino L., Evans-Molina C., DiMeglio.L., Goland R., Wilson D.M., et al. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia. 2020; 63(3): 588–596. DOI: 10.1007/s00125-019-05047-w

9. Haller M.J., Bell K.J., Besser R.E.J., Casteels K., Couper J.J., Craig M.Е., et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. Hormone Research in Pediatrics. 2024; 11: 1–17. DOI: 10.1159/000543035

10. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes–2024. Diabetes Care. 2024; 47(1): 20– 42. DOI: 10.2337/dc24-S002

11. Early diagnosis and treatment of type 1 diabetes mellitus. Issues of clinical feasibility, organization, and accessibility of medical care. Resolution on the results of the Expert Council held on December 17, 2024, Moscow. Medicinskie tekhnologii. Ocenka i vybor. 2025; 47(2): 10–17. (in Russ.) DOI: 10.17116/medtech20254702110

12. Nedogoda S.V., Galstyan G.R., Laptev D.N., Salasyuk A.S., Barykina I.N., Lutova V.O., et al. Clinical and economic analysis of diabetes type 1 screening in children in the Russian Federation. Medicinskie tekhnologii. Ocenka i vybor. 2024; 46(3): 104–114. (in Russ). DOI: 10.17116/medtech202446031104

13. Besser R.E.J., Ng S.M., Gregory J.W., Dayan C.M., Randell T., Barrett T. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Archives Disease Childhood. 2022; 107(9): 790–795. DOI: 10.1136/archdischild-2021-321864

14. Insel R.A., Dunne J.L., Atkinson M.A., Chiang J.L., Dabelea D., Gottlieb P.A., et al. Staging presymptomatic type 1 diabetes: a scientifi c statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015; 38(10): 1964- 1974. DOI: 10.2337/dc15-1419

15. Chudakov D.M., Petryaykina E.E., Demina E.S., Lukyanov S.A., Timofeev A.V. Perspectives on the use of anti-CD20 immunotherapy in the treatment of type 1 diabetes mellitus in children and adolescents (analytical review). Pediatria n.a. G.N. Speransky. 2023; 102 (2): 100–116. (in Russ) DOI: 10.24110/0031-403X-2023-102-2-100-116

16. Herold K.C., Bundy B.N., Long S.A., Bluestone J.A., DiMeglio L.A., Dufort M.J., et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7): 603–613. DOI: 10.1056/NEJMoa1902226

17. Laptev D.N., Dedov I.I. Towards prevention of type 1 diabetes: FDA approved first drug with potential to delay clinical stage of disease. Sakharnyj diabet. 2022; 25(6): 576–579. (in Russ) DOI: 10.14341/DM12988

Review

For citations:

Alimova I.L. Type 1 diabetes: early diagnosis and treatment prospects. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2025;70(6):5-10. (In Russ.) https://doi.org/10.21508/1027-4065-2025-70-6-5-10

JATS XML